Long-term effects of spironolactone on kidney function and hyperkalemia-associated hospitalization in patients with chronic kidney disease

Journal of Clinical Medicine

Volumn 7, Issue 11, 2018, Pages

  Yang, Chen Ta ^a   Kor, Chew Teng ^a   Hsieh, Yao Peng ^a,b,c  

^a CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Chronic kidney disease (CKD); End stage renal disease (ESRD); Major adverse cardiovascular events (MACE); Mortality; Spironolactone

Indexed keywords

SPIRONOLACTONE;

ADULT; ALL CAUSE MORTALITY; ARTICLE; ATRIAL FIBRILLATION; CARDIOVASCULAR DISEASE; CHARLSON COMORBIDITY INDEX; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE SEVERITY; DOSE RESPONSE; END STAGE RENAL DISEASE; FEMALE; HOSPITALIZATION; HUMAN; HYPERKALEMIA; HYPERTENSION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE;

EID: 85075408731     PISSN: None     EISSN: 20770383     Source Type: Journal    
DOI: 10.3390/jcm7110459     Document Type: Article

References (35)

1. Gansevoort, R.T.; Correa-Rotter, R.; Hemmelgarn, B.R.; Jafar, T.H.; Heerspink, H.J.; Mann, J.F.; Matsushita, K.; Wen, C.P. Chronic kidney disease and cardiovascular risk: Epidemiology, mechanisms, and prevention. Lancet 2017, 382, 339–352. [CrossRef]
2. Tonelli, M.; Wiebe, N.; Culleton, B.; House, A.; Rabbat, C.; Fok, M.; McAlister, F.; Garg, A.X. Chronic kidney disease and mortality risk: A systematic review. J. Am. Soc. Nephrol. 2006, 17, 2034–2047. [CrossRef] [PubMed]
3. Tomiyama, C.; Higa, A.; Dalboni, M.A.; Cendoroglo, M.; Draibe, S.A.; Cuppari, L.; Carvalho, A.B.; Neto, E.M.; Canziani, M.E. The impact of traditional and nontraditional risk factors on coronary calcification in pre-dialysis patients. Nephrol. Dial. Transpl. 2006, 21, 2464–2471. [CrossRef] [PubMed]
4. Brenner, B.M.; Cooper, M.E.; de Zeeuw, D.; Keane, W.F.; Mitch, W.E.; Parving, H.H.; Remuzzi, G.; Snapinn, S.M.; Zhang, Z.; Shahinfar, S.; et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 2001, 345, 861–869. [CrossRef] [PubMed]
5. Jafar, T.H.; Schmid, C.H.; Landa, M.; Giatras, I.; Toto, R.; Remuzzi, G.; Maschio, G.; Brenner, B.M.; Kamper, A.; Zucchelli, P.; et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann. Intern. Med. 2001, 135, 73–87. [CrossRef] [PubMed]
6. Ma, L.J.; Fogo, A.B. Role of angiotensin II in glomerular injury. Semin. Nephrol. 2001, 21, 544–553. [CrossRef] [PubMed]
7. McElvie, R.S.; Yusuf, S.; Pericak, D.; Avezum, A.; Burns, R.J.; Probstfield, J.; Tsuyuki, R.T.; White, M.; Rouleau, J.; Latini, R.; et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. Circulation 1999, 10, 1056–1064. [CrossRef]
8. Bolignano, D.; Palmer, S.C.; Navaneethan, S.D.; Strippoli, G.F. Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst. Rev. 2014, 4, CD007004. [CrossRef] [PubMed]
9. Ng, K.P.; Arnold, J.; Sharif, A.; Gill, P.; Townend, J.N.; Ferro, C.J. Cardiovascular actions of mineralocorticoid receptor antagonists in patients with chronic kidney disease: A systematic review and meta-analysis. J. Renin. Angiotensin Aldosterone Syst. 2015, 16, 599–613. [CrossRef] [PubMed]
10. Epstein, M. Mineralocorticoid receptor antagonists: Part of an emerging treatment paradigm for chronic kidney disease. Lancet Diabetes Endocrinol. 2014, 2, 925–927. [CrossRef]
11. Alfie, J.; Aparicio, L.S.; Waisman, G.D. Current strategies to achieve further cardiac and renal protection through enhanced renin-angiotensin-aldosterone system inhibition. Rev. Recent Clin. Trials 2011, 6, 134–146. [PubMed]
12. Schjoedt, K.J.; Andersen, S.; Rossing, P.; Tarnow, L.; Parving, H.H. Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia 2004, 47, 1936–1939. [CrossRef] [PubMed]
13. Cerezo, C.; Ruilope, L.M.; Segura, J.; Garcia-Donaire, J.A.; de la Cruz, J.J.; Banegas, J.R.; Waeber, B.; Rabelink, T.J.; Messerli, F.H. Microalbuminuria breakthrough under chronic renin-angiotensin-aldosterone system suppression. J. Hypertens. 2012, 30, 204–209. [CrossRef] [PubMed]
14. Edwards, N.C.; Steeds, R.P.; Stewart, P.M.; Ferro, C.J.; Townend, J.N. Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: A randomized controlled trial. J. Am. Coll. Cardiol. 2009, 54, 505–512. [CrossRef] [PubMed]
15. Rossing, K.; Schjoedt, K.J.; Smidt, U.M.; Boomsma, F.; Parving, H.H. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: A randomized, double-masked, cross-over study. Diabetes Care 2005, 28, 2106–2112. [CrossRef] [PubMed]
16. Tylicki, L.; Rutkowski, P.; Renke, M.; Larczyński, W.; Aleksandrowicz, E.; Lysiak-Szydlowska, W.; Rutkowski, B. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: An open-label crossover randomized controlled trial. Am. J. Kidney Dis. 2008, 52, 486–493. [CrossRef] [PubMed]
17. Wang, W.; Li, L.; Zhou, Z.; Gao, J.; Sun, Y. Effect of spironolactone combined with angiotensin converting enzyme inhibitors and/or angiotensin II receptor blockers on chronic glomerular disease. Exp. Ther. Med. 2013, 6, 1527–1531. [CrossRef] [PubMed]
18. Currie, G.; Taylor, A.H.; Fujita, T.; Ohtsu, H.; Lindhardt, M.; Rossing, P.; Boesby, L.; Edwards, N.C.; Ferro, C.J.; Townend, J.N.; et al. Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: A systematic review and meta-analysis. BMC Nephrol. 2016, 17, 127. [CrossRef] [PubMed]
19. Bakris, G.L.; Agarwal, R.; Chan, J.C.; Cooper, M.E.; Gansevoort, R.T.; Haller, H.; Remuzzi, G.; Rossing, P.; Schmieder, R.E.; Nowack, C.; et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy: A randomized clinical trial. JAMA 2015, 314, 884–894. [CrossRef] [PubMed]
20. Taira, M.; Toba, H.; Murakami, M.; Iga, I.; Serizawa, R.; Murata, S.; Kobara, M.; Nakata, T. Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats. Eur. J. Pharmacol. 2008, 589, 264–271. [CrossRef] [PubMed]
21. Rocha, R.; Rudolph, A.E.; Frierdich, G.E.; Nachowiak, D.A.; Kekec, B.K.; Blomme, E.A.; McMahon, E.G.; Delyani, J.A. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am. J. Physiol. Heart Circ. Physiol. 2002, 283, H1802–H1810. [CrossRef] [PubMed]
22. Terada, Y.; Ueda, S.; Hamada, K.; Shimamura, Y.; Ogata, K.; Inoue, K.; Taniguchi, Y.; Kagawa, T.; Horino, T.; Takao, T. Aldosterone stimulates nuclear factor-kappa b activity and transcription of intercellular adhesion molecule-1 and connective tissue growth factor in rat mesangial cells via serum-and glucocorticoid-inducible protein kinase-1. Clin. Exp. Nephrol. 2012, 16, 81–88. [CrossRef] [PubMed]
23. Bauersachs, J.; Jaisser, F.; Toto, R. Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases. Hypertension 2015, 65, 257–263. [CrossRef] [PubMed]
24. Queisser, N.; Amann, K.; Hey, V.; Habib, S.L.; Schupp, N. Blood pressure has only minor influence on aldosterone-induced oxidative stress and DNA damage in vivo. Free Radic. Biol. Med. 2013, 54, 17–25. [CrossRef] [PubMed]
25. Rocha, R.; Stier, C.T., Jr.; Kifor, I.; Ochoa-Maya, M.R.; Rennke, H.G.; Williams, G.H.; Adler, G.K. Aldosterone: A mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000, 141, 3871–3878. [CrossRef] [PubMed]
26. Fukuda, S.; Horimai, C.; Harada, K.; Wakamatsu, T.; Fukasawa, H.; Muto, S.; Itai, A.; Hayashi, M. Aldosterone-induced kidney injury is mediated by NFκB activation. Clin. Exp. Nephrol. 2011, 15, 41–49. [CrossRef] [PubMed]
27. Lian, M.; Hewitson, T.D.; Wigg, B.; Samuel, C.S.; Chow, F.; Becker, G.J. Long-term mineralocorticoid receptor blockade ameliorates progression of experimental diabetic renal disease. Nephrol. Dial. Transpl. 2012, 27, 906–912. [CrossRef] [PubMed]
28. Chen, C.; Liang, W.; Jia, J.; van Goor, H.; Singhal, P.C.; Ding, G. Aldosterone induces apoptosis in rat podocytes: Role of PI3-K/Akt and p38MAPK signaling pathways. Nephron Exp. Nephrol. 2009, 113, e26–e34. [CrossRef] [PubMed]
29. Kobayashi, N.; Hara, K.; Tojo, A.; Onozato, M.L.; Honda, T.; Yoshida, K.; Mita, S.; Nakano, S.; Tsubokou, Y.; Matsuoka, H. Eplerenone shows renoprotective effect by reducing LOX-1-mediated adhesion molecule, PKCepsilon-MAPK-p90RSK, and Rho-kinase pathway. Hypertension 2005, 45, 538–544. [CrossRef] [PubMed]
30. Perez-Rojas, J.M.; Derive, S.; Blanco, J.A.; Cruz, C.; Martínez de la Maza, L.; Gamba, G.; Bobadilla, N.A. Renocortical mRNA expression of vasoactive factors during spironolactone protective effect in chronic cyclosporine nephrotoxicity. Am. J. Physiol. Ren. Physiol. 2005, 289, F1020–F1030. [CrossRef] [PubMed]
31. Luther, J.M.; Luo, P.; Wang, Z.; Cohen, S.E.; Kim, H.S.; Fogo, A.B.; Brown, N.J. Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin ii-induced cardiac, renal, and vascular injury. Kidney Int. 2012, 82, 643–651. [CrossRef] [PubMed]
32. Nagase, M.; Shibata, S.; Yoshida, S.; Nagase, T.; Gotoda, T.; Fujita, T. Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker. Hypertension 2006, 47, 1084–1093. [CrossRef] [PubMed]
33. Nemeth, Z.; Kokeny, G.; Godo, M.; Mózes, M.; Rosivall, L.; Gross, M.L.; Ritz, E.; Hamar, P. Increased renoprotection with ACE inhibitor plus aldosterone antagonist as compared to monotherapies—The effect on podocytes. Nephrol. Dial. Transpl. 2009, 24, 3640–3651. [CrossRef] [PubMed]
34. Tseng, W.C.; Liu, J.S.; Hung, S.C.; Kuo, K.L.; Chen, Y.H.; Tarng, D.C.; Hsu, C.C. Effect of spironolactone on the risks of mortality and hospitalization for heart failure in pre-dialysis advanced chronic kidney disease: A nationwide population-based study. Int. J. Cardiol. 2017, 238, 72–78. [CrossRef] [PubMed]
35. Benson, K.; Hartz, A.J. A comparison of observational studies and randomized, controlled trials. N. Engl. J. Med. 2000, 342, 1878–1886. [CrossRef] [PubMed]